 Autolus Therapeutics plc AUTL, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced new data highlighting progress on its AUTO1 program, the companys CAR T cell therapy being investigated in the ongoing ALLCAR Phase 1 study of relapsed refractory adult B-Acute Lymphocytic Leukemia ALL, at the European Hematology Association EHA25 Virtual Congress beginning June 11. As of the data cut-off date of May 13, 2020, 19 patients had received AUTO1. AUTO1 was well tolerated, with no patients experiencing Grade 3 CRS. 